Favorable effects of early insulin secretion by nateglinide on postprandial hyperlipidemia in patients with type 2 diabetes.
Ai
Masumi
M
Tanaka
Akira
A
Ogita
Kyoko
K
Shimokado
Kentaro
K
D003510:Cyclohexanes / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000517:prevention & control*; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D000077715:Nateglinide; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019518:Postprandial Period; D014280:Triglycerides / Q000097:blood
D003510:Cyclohexanes; D007004:Hypoglycemic Agents; D007328:Insulin; D014280:Triglycerides; D000077715:Nateglinide; D010649:Phenylalanine